CIR according to high-risk genetics and MRD response. CIR is shown for patients also investigated for relevant oncogenetic events, according to the presence of high-risk genetic characteristics (MLL gene rearrangement and/or focal IKZF1 gene deletion in BCP-ALL patients; high-risk NOTCH1/FBXW7/RAS/PTEN profile in T-ALL patients) and MRD1 level (using a 10⁻⁴ cutoff). (A) In BCP-ALL patients, MRD1 level discriminates high-risk patients in good- as well as high-risk genetic subgroups (HR, 2.69 [1.28-5.68] and 2.63 [1.23-5.63]; P = .009 and 0.013, respectively), whereas no significant difference in CR was observed in patients with a low MRD1 level, whatever their genetic characteristics (P = .18). (B) In T-ALL patients, a high-risk genetic profile discriminated high-risk patients, whatever the level of MRD1 (HR, 4.27 [1.52-12.01] and 4.04 [1.17-13.97]; P = .006 and 0.027, respectively), whereas no significant difference in CIR was observed in patients with a good-risk genetic profile, whatever their MRD1 level (P = .19).